GILD:
The current market price is 133.16, reflecting a percentage increase of +0.74% from the previous price.
Support and Resistance Levels
Support levels are 133.16, 133.16, and 133.16. Resistance levels are 133.16, 133.16, and 133.16. The pivot point is 133.16.
Indicators
The current RSI is 40.43, showing a declining trend from the history. The ATR stands at 0.34191. The Parabolic SAR is at 136.03016, indicating a recent upward phase. MACD shows a value of -0.31715 with a bearish trend as the MACD is below the signal line.
Market Sentiment
The price is at the pivot point of 133.16; hence, bearish conditions are anticipated as indicators are not favoring upward movement.
GILD Signals & Technical Analysis
Last Updated: <% indicators.interval.updated|date:'MMM d, y h:mm:ss a' %>
Gilead Sciences, Inc. (NASDAQ: GILD) is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics in areas of unmet medical need. Founded in 1987 and headquartered in Foster City, California, Gilead has established itself as a leader in the development of antiviral drugs that combat HIV, hepatitis B and C, influenza, and COVID-19. With a commitment to advancing global health, Gilead's research and development efforts focus on creating transformative medicines for patients worldwide.
Over the years, Gilead has built a strong market position, particularly in the field of antiviral therapies. The company gained widespread recognition for its groundbreaking treatments, including the antiretroviral therapy Truvada, which has played a crucial role in combating the HIV epidemic. Additionally, Gilead's innovative approach to hepatitis C treatment, notably with its drug Harvoni, revolutionized care practices and significantly reduced the disease's prevalence. As of 2023, Gilead continues to strengthen its presence in the market with robust pipelines that encompass other therapeutic areas, including oncology and inflammation.
In terms of financial performance, Gilead Sciences has demonstrated resilience amidst a dynamic healthcare landscape. The company reported a revenue of $27 billion for the fiscal year 2022, reflecting a steady demand for its key products despite emerging competition. Gilead's strategic investments in research and development have positioned it for sustained growth, with an R&D expenditure exceeding $5 billion in the same year. This commitment underscores Gilead's focus on innovation and its ability to adapt to changing healthcare needs.
Gilead Sciences is also recognized for its global initiatives aimed at expanding access to its therapies, particularly in low- and middle-income countries. The company's partnerships with various organizations, including governments and non-profits, highlight its dedication to improving health outcomes worldwide. As Gilead continues to evolve, it remains committed to delivering cutting-edge solutions that enhance the quality of life for patients everywhere.
<% (signals.list.current.rate).substr(0,7) %>
<% signal.analyst %>
